Changde Zhang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1259752/publications.pdf Version: 2024-02-01



CHANCE ZHANC

#	Article	IF	CITATIONS
1	Fulvestrant-3 Boronic Acid (ZB716): An Orally Bioavailable Selective Estrogen Receptor Downregulator (SERD). Journal of Medicinal Chemistry, 2016, 59, 8134-8140.	6.4	65
2	Boronic prodrug of 4-hydroxytamoxifen is more efficacious than tamoxifen with enhanced bioavailability independent of CYP2D6 status. BMC Cancer, 2015, 15, 625.	2.6	32
3	Rational Design of a Boron-Modified Triphenylethylene (GLL398) as an Oral Selective Estrogen Receptor Downregulator. ACS Medicinal Chemistry Letters, 2017, 8, 102-106.	2.8	32
4	Biocompatible Boron-Containing Prodrugs of Belinostat for the Potential Treatment of Solid Tumors. ACS Medicinal Chemistry Letters, 2018, 9, 149-154.	2.8	32
5	ZB716, a steroidal selective estrogen receptor degrader (SERD), is orally efficacious in blocking tumor growth in mouse xenograft models. Oncotarget, 2018, 9, 6924-6937.	1.8	27
6	Point-of-Care Determination of Acetaminophen Levels with Multi-Hydrogen Bond Manipulated Single-Molecule Recognition (eMuHSiR). Analytical Chemistry, 2018, 90, 4733-4740.	6.5	25
7	Metabolism, pharmacokinetics, and bioavailability of ZB716, a Steroidal Selective Estrogen Receptor Downregulator (SERD). Oncotarget, 2017, 8, 103874-103889.	1.8	17
8	Monomethyl Auristatin E Phosphate Inhibits Human Prostate Cancer Growth. Prostate, 2016, 76, 1420-1430.	2.3	16
9	Development of a bioavailable boron-containing PI-103 Bioisostere, PI-103BE. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127258.	2.2	11
10	Metabolism and Pharmacokinetic Study of the Boron-Containing Prodrug of Belinostat (ZL277), a Pan HDAC Inhibitor with Enhanced Bioavailability. Pharmaceuticals, 2019, 12, 180.	3.8	8
11	Asymmetric 1,5-diarylpenta-1,4-dien-3-ones: Antiproliferative activity in prostate epithelial cell models and pharmacokinetic studies. European Journal of Medicinal Chemistry, 2017, 137, 263-279.	5.5	7
12	Structure-activity relationship and pharmacokinetic studies of 3-O-substitutedflavonols as anti-prostate cancer agents. European Journal of Medicinal Chemistry, 2018, 157, 978-993.	5.5	7
13	Optimization of diarylpentadienones as chemotherapeutics for prostate cancer. Bioorganic and Medicinal Chemistry, 2018, 26, 4751-4760.	3.0	4
14	Fulvestrant-3-Boronic Acid (ZB716) Demonstrates Oral Bioavailability and Favorable Pharmacokinetic Profile in Preclinical ADME Studies. Pharmaceuticals, 2021, 14, 719.	3.8	4
15	Methoxyacetic acid suppresses prostate cancer cell growth by inducing growth arrest and apoptosis. American Journal of Clinical and Experimental Urology, 2014, 2, 300-12.	0.4	3